Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides

被引:33
作者
Blaschke, V
Reich, K
Middel, P
Letschert, M
Sachse, F
Harwix, S
Neumann, C
机构
[1] Univ Gottingen, Dept Dermatol, D-37075 Gottingen, Germany
[2] Univ Gottingen, Dept Pathol, D-37075 Gottingen, Germany
关键词
chemotaxis; cytokines; quantitative competitive reverse transcription-polymerase chain reaction;
D O I
10.1046/j.1523-1747.1999.00717.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Interleukin-16 is a soluble ligand to the CD4 molecule with chemotactic properties for CD4(+) cells and a competence growth factor for CD4(+) T cells, upregulating HLA-DR and the interleukin-2 receptor CD25, There is also evidence for a synergistic effect of interleukin-16 and interleukin-2 on the activation of CD4(+) T cells. The infiltrate in mycosis fungoides, the most common cutaneous T cell lymphoma, is typically CD4(+). We tested the possibility that interleukin-16 is involved in the formation and progression of these lesions. By reverse transcription-polymerase chain reaction, interleukin-16 mRNA was detected in 18 of 18 mycosis fungoides lesions investigated. By competitive reverse transcription-polymerase chain reaction, interleukin-16 mRNA expression increased with disease stage. Secreted interleukin-16 was detected by enzyme-linked immunosorbent assay in both Th1- and Th2-like T cell clones (as characterized by their production of interferon-gamma and interleukin-4) grown from lesional dermis and epidermis, By immunohistochemistry and in situ hybridization, infiltrating lymphocytes were the main producers of interleukin-16 whereas keratinocytes and endothelial cells remained negative, Atypical cells with convoluted nuclei were also positive. In advanced mycosis fungoides stages, many blast-like cells were positive, but some larger blasts remained negative. Interleukin-16 expression correlated positively with the expression of interleukin-2 and its receptor CD25 in individual skin lesions. Interleukin-2 expression, however, was weak or absent in samples from uninvolved skin, healthy controls and lesional psoriasis, Given the biologic properties of interleukin-16 and the parallel activation of the interleukin-2/CD25 pathway, interleukin-16 might be involved in the recruitment and stimulation of CD4(+) lymphocytes in mycosis fungoides lesions and therefore contribute to the perpetuation of the associated cutaneous inflammation.
引用
收藏
页码:658 / 663
页数:6
相关论文
共 18 条
[1]   Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor [J].
Baier, M ;
Bannert, N ;
Werner, A ;
Lang, K ;
Kurth, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (10) :5273-5277
[2]   Exclusive expression of the Gs-linked prostaglandin E(2) receptor subtype 4 mRNA in human mononuclear Jurkat and KM-3 cells and coexpression of subtype 4 and 2 mRNA in U-937 cells [J].
Blaschke, V ;
Jungermann, K ;
Puschel, GP .
FEBS LETTERS, 1996, 394 (01) :39-43
[3]  
BREITSCHOPF H, 1992, ACTA NEUROPATHOL, V84, P581
[4]  
Cruikshank WW, 1996, J IMMUNOL, V157, P5240
[5]   EARLY IDENTIFICATION OF INTERLEUKIN-16 (LYMPHOCYTE CHEMOATTRACTANT FACTOR) AND MACROPHAGE INFLAMMATORY PROTEIN 1-ALPHA (MIP1-ALPHA) IN BRONCHOALVEOLAR LAVAGE FLUID OF ANTIGEN-CHALLENGED ASTHMATICS [J].
CRUIKSHANK, WW ;
LONG, A ;
TARPY, RE ;
KORNFELD, H ;
CARROLL, MP ;
TERAN, L ;
HOLGATE, ST ;
CENTER, DM .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 13 (06) :738-747
[6]   MOLECULAR AND FUNCTIONAL-ANALYSIS OF A LYMPHOCYTE CHEMOATTRACTANT FACTOR - ASSOCIATION OF BIOLOGIC FUNCTION WITH CD4 EXPRESSION [J].
CRUIKSHANK, WW ;
CENTER, DM ;
NISAR, N ;
WU, MN ;
NATKE, B ;
THEODORE, AC ;
KORNFELD, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (11) :5109-5113
[7]  
CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817
[8]   ANALYSIS OF CYTOKINE MESSENGER-RNA AND DNA - DETECTION AND QUANTITATION BY COMPETITIVE POLYMERASE CHAIN-REACTION [J].
GILLILAND, G ;
PERRIN, S ;
BLANCHARD, K ;
BUNN, HF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (07) :2725-2729
[9]  
LEFKOVITS I, 1984, IMMUNOL TODAY, V5, P261
[10]  
Parada NA, 1998, J IMMUNOL, V160, P2115